FIELD: pharmacology.
SUBSTANCE: invention relates to a compound of formula 2 
,
wherein independently for each case R1 is hydrogen; each R2 and R3 is independently selected from the group consisting of hydrogen; (C1-C6)alkyl, optionally substituted with OH; heteroaryl containing 6 atoms in the ring, 1 atom of which is N, and the remaining ones are C atoms (pyridine); heterocyclyl containing 5 or 6 ring atoms, 1 atom of which is N and the remaining ones are C atoms (piperidine or pyrrolidine) optionally substituted by a group selected from methyl, phenyl, pyridinylmethyl, quinolinylmethyl, pyridinylmethyl, piperidinylmethyl or azetidinylmethyl; aryl (C1-C6)alkyl, wherein aryl contains 6 ring atoms, optionally substituted amino or CH2NH2, where (C1-C6)alkyl is optionally substitutedby OH; heteroaryl (C1-C6)alkyl, wherein heteroaryl contains 5 to 9 ring atoms, of which 1 to 2 are heteroatoms selected from N and S, and the remaining atoms are C atoms (indole, pyridine, thiophene, benzimidazole, pyrazole), wherein heteroaryl is optionally is replaced by ethyl; heterocycle (C1-C6)alkyl, wherein the heterocycle contains 6 ring atoms, 1 atom of which is N and the remaining ones are C atoms (piperidine) optionally substituted by methyl; and - [C(R4)2]p-R5, or R2 and R3 are joined together to form an optionally substituted heterocyclic ring containing 5-10 atoms, of which 1 to 2 are heteroatoms selected from N and O, and the remaining ones are C atoms; R20 is selected from the group consisting of hydrogen; heterocyclyl containing 6 ring atoms, 1 atom of which is a heteroatom selected from N, and the remaining atoms are C atoms (piperidinyl); halogen (C1-C6)alkyl; trifluoromethyl; fluorine (C1-C6)alkyl; -O-[C(R4)2]p-R5; -OR16, where R16 is methyl; and amino, which is -N(R50)(R51), where each R50 and R51 is independently hydrogen, (C1-C6)alkyl, optionally substituted by methoxy, or - (CH2)m-R61, where R61 is an aryl containing 6 ring atoms, and m is an integer from 1 to 8. The invention also relates to specific compounds as defined in the claims. The compounds of the invention are for cancer treatment or effect on apoptosis, by administration of a therapeutically effective amount of a compound to a mammal in need thereof.
EFFECT: aminopyrimidine compounds for cancer treatment.
24 cl, 30 tbl, 251 ex, 53 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOPYRIMIDINE KINASE INHIBITORS | 2012 |
|
RU2674017C2 |
| HYBRID DERIVATIVES OF (1H-1,2,4) TRIAZOLE AND SULPHUR-CONTAINING HETEROCYCLES: DERIVATIVES OF THIAZOLIDINE-2,4-DIONE, THIOMORPHOLINE-3-ONE, AND 1,4-THIAZEPAN-3-ONE, EXHIBITING ANTIMICROBIAL ACTIVITY | 2020 |
|
RU2771027C1 |
| PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | 2010 |
|
RU2607453C2 |
| HYBRID AMIDES BASED ON TRIAZOLE AND THIAZOLIDINE HAVING ANTIMICROBIAL ACTIVITY | 2018 |
|
RU2703997C1 |
| 1-SULFONYL-1,3-DIHYDROINDOLE-2-ONES, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHOD FOR THEIR PREPARING AND APPLYING | 2003 |
|
RU2259999C2 |
| INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2288228C2 |
| IMIDE MODULATORS OF PROTEOLYSIS AND METHODS FOR USING THEM | 2015 |
|
RU2738833C2 |
| HETEROCYCLIC COMPOUND STIMULATING OR INDUCING HAIR OR EYELASHES GROWTH AND/OR PREVENTING THEIR FALLING DOWN, COMPOSITION THAT CONTAINS THIS COMPOUND, ITS APPLICATION | 2003 |
|
RU2316325C2 |
| HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2010 |
|
RU2558141C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
